Cleveland-Immunoscintigraphy scanning, criticized in the past for poor performance in imaging metastatic disease, may have found a reliable niche in the treatment of prostate cancer.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.